Not provided
Not provided
Not provided
Not provided
Not provided
12 month follow up data not collected due to pandemic disruptions
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Carestar Foundation | OTHER |
Not provided
Not provided
Not provided
This is a phase 4, open-label, feasibility study of extended release naltrexone (Vivitrol, Alkermes Pharmaceutical) and case management for treatment of alcohol use disorders in the ED.
Excess alcohol use is a major cause of morbidity and mortality and contributes to a large number of emergency department (ED) visits. The rate of alcohol-related ED visits is increasing, and there is evidence that this increase may be driven by a subset of patients who frequently visit the ED due to an underlying alcohol use disorder (AUD). The proposed study will assess the feasibility of implementing a multimodal treatment for AUD in the emergency department for 25 patients with AUD. The rationale for including each component of the multimodal treatment is outlined below.
Pharmacotherapy is recommended as the standard of care for alcohol use disorders. Of the four drugs approved by the FDA for treatment of alcohol use disorder, extended release naltrexone has been found to be superior at reducing healthcare utilization, increasing detoxification facility use, and reducing total cost. Fewer than 1 in 4 patients with AUD currently receives treatment with an FDA approved agent and use of these drugs in EDs is virtually non-existent.
ED patients with alcohol use disorders frequently suffer from multiple medical, mental health, and social problems that influence their health. Providing such patients with case management services has shown promise in improving health related outcomes while curbing ED utilization and healthcare costs.
Regardless of comorbidity, limited access to substance use and mental health services is a significant barrier to receiving treatment, and large disparities exist in access based on income level. Facilitated referrals, where a healthcare worker communicates with the patient and service providers and assists the patient with obtaining follow up, have been used effectively to improve access to specialty care after ED discharge. Case managers are familiar with community treatment resources and are well versed in providing facilitated referrals.
The primary hypothesis is that implementing this multimodal treatment will be feasible in an ED setting and will reduce alcohol use. Feasibility measures (recruitment, retention, continuation of treatment after the trial) are the primary outcomes. The intent of the intervention is to change drinking behavior in a way that benefits participants' health and quality of life. As such, we will conduct a limited efficacy assessment. Treatment efficacy will be assessed by comparing alcohol consumption, quality of life, and life consequences related to alcohol use before and after the intervention.
The primary efficacy outcome is change in total alcohol consumption measured by a 2 week timeline follow back. Change from baseline will be assessed after the 3 month intervention period, and at the conclusion of the study follow up period for all outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multimodal Intervention | Experimental | The intervention is multimodal and consists of:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vivitrol (Extended Release Naltrexone) | Drug | Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participants Retained in Study at 3 Months | Percentage of enrolled participants who attend final study visit at the end of the intervention period | 3 months |
| Retention at 12 Months | Percentage of enrolled participants who complete final study visit at the end of the follow up periods | 12 months |
| Change in Daily Total Alcohol Consumption From Baseline at 3 Months | Self-reported total daily alcohol consumption at 3 months, compared to baseline | 3 months after enrollment |
| Change in Total Alcohol Consumption at 12 Months | Change in self-reported total daily alcohol consumption from baseline | 12 months after enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Quality of Life Score at 3 Months | Kemp Quality of Life score at 3 months compared to baseline. Score is 1-7 with higher scores indicating higher quality of life. | 3 months after enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Substance Use Treatment Utilization | percentage of participants self-reporting engagement in community substance use treatment programs | 12 months |
| Recruitment | Percentage of those approached who enroll in the study |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maria Raven, MD | University of California, San Francisco | Principal Investigator |
| Charles E Murphy IV, MD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94122 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36328851 | Derived | Murphy CE 4th, Coralic Z, Wang RC, Montoy JCC, Ramirez B, Raven MC. Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department. Ann Emerg Med. 2023 Apr;81(4):440-449. doi: 10.1016/j.annemergmed.2022.08.453. Epub 2022 Oct 31. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Multimodal Intervention | The intervention is multimodal and consists of:
Extended Release Naltrexone: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 11, 2020 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 12 months |
| Continued Naltrexone Use After Intervention Period | Percentage of enrolled who self reported continuing treatment with naltrexone through their primary physician after the end of the study intervention period | 3 months |
| Change in ED Utilization | Change in the number of emergency department visits determined by electronic medical record review | 12 months before and after enrollment |
| Change in WHO Drinking Risk Level | Change in World Health Organization drinking risk level from baseline. Risk levels are scored 1-4 with higher scores indicating more severe health risk from alcohol use | 3 months after enrollment |
| Change in Alcohol Related Life Consequences (Short Inventory of Problems Scale, Version 2R: SIP-2R) | Change in life consequences due to alcohol use from baseline as measured by revised short inventory of problems (score 0-45 with higher scores indicating more severe alcohol related life consequences) | 3 months after enrollment |
| Receipt of All Study Naltrexone Injections | Percentage of participants receiving all 3 scheduled naltrexone injections received | 3 months |
| Screened for Eligibility | Screened for eligibility based on pre-screening result of being interested and willing to undergo screened |
|
| Enrolled and Received First Injection |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Multimodal Intervention | The intervention is multimodal and consists of:
Extended Release Naltrexone: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Full Range | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| ||||||||||||||||||
| Annual income | Median | Inter-Quartile Range | U.S. Dollars/ year |
| |||||||||||||||||
| Education | Highest Grade achieved | Median | Full Range | years |
| ||||||||||||||||
| Employed | Count of Participants | Participants |
| ||||||||||||||||||
| Stable housing | Count of Participants | Participants |
| ||||||||||||||||||
| Comorbid serious mental illness | Count of Participants | Participants |
| ||||||||||||||||||
| Tobacco use | Count of Participants | Participants |
| ||||||||||||||||||
| Any comorbid substance use | Count of Participants | Participants |
| ||||||||||||||||||
| Amphetamines | comorbid use | Count of Participants | Participants |
| |||||||||||||||||
| Cocaine | comorbid use | Count of Participants | Participants |
| |||||||||||||||||
| Cannabis | comorbid use | Count of Participants | Participants |
| |||||||||||||||||
| Alcohol Use Disorder Identification Test (AUDIT) score | alcohol use disorder identification test consumption score, range 0-12, score > 4 consistent with alcohol misuse and possible liver damage | Median | Inter-Quartile Range | units on a scale |
| ||||||||||||||||
| Daily alcohol consumption over the past 14 days | 1 drink contains 14 grams of ethyl alcohol | Median | Inter-Quartile Range | drinks per day |
| ||||||||||||||||
| WHO drinking risk level | Risk levels for health consequences due to alcohol use: 4 Very High, 3 High, 2 Moderate, 1 Low | Median | Inter-Quartile Range | units on a scale |
| ||||||||||||||||
| Short Inventory of Problems Score (SIP-2R) | Possible score 0-45 with higher scores indicative of more alcohol-related problems. Scores 30-45 and 23-29 indicate "Very High" and "High" levels of alcohol related problems | Median | Inter-Quartile Range | units on a scale |
| ||||||||||||||||
| Kemp Quality of Life Scale Score | Score range 1-7 with high scores indicating better quality of life | Mean | Standard Deviation | units on a scale |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participants Retained in Study at 3 Months | Percentage of enrolled participants who attend final study visit at the end of the intervention period | Posted | Count of Participants | Participants | 3 months |
|
|
| |||||||||||||||||||||||||||
| Primary | Retention at 12 Months | Percentage of enrolled participants who complete final study visit at the end of the follow up periods | These data were not collected due to COVID-19 pandemic disruptions. | Posted | 12 months |
|
| |||||||||||||||||||||||||||||
| Primary | Change in Daily Total Alcohol Consumption From Baseline at 3 Months | Self-reported total daily alcohol consumption at 3 months, compared to baseline | Posted | Median | 95% Confidence Interval | drinks per day | 3 months after enrollment |
|
| |||||||||||||||||||||||||||
| Primary | Change in Total Alcohol Consumption at 12 Months | Change in self-reported total daily alcohol consumption from baseline | These data were not collected due to COVID-19 pandemic disruptions. | Posted | 12 months after enrollment |
|
| |||||||||||||||||||||||||||||
| Secondary | Change in Quality of Life Score at 3 Months | Kemp Quality of Life score at 3 months compared to baseline. Score is 1-7 with higher scores indicating higher quality of life. | Posted | Mean | 95% Confidence Interval | score on a scale | 3 months after enrollment |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Substance Use Treatment Utilization | percentage of participants self-reporting engagement in community substance use treatment programs | Not Posted | 12 months | Participants | |||||||||||||||||||||||||||||||
| Other Pre-specified | Recruitment | Percentage of those approached who enroll in the study | Not Posted | 12 months | Participants | |||||||||||||||||||||||||||||||
| Other Pre-specified | Continued Naltrexone Use After Intervention Period | Percentage of enrolled who self reported continuing treatment with naltrexone through their primary physician after the end of the study intervention period | Posted | Count of Participants | Participants | 3 months |
|
| ||||||||||||||||||||||||||||
| Other Pre-specified | Change in ED Utilization | Change in the number of emergency department visits determined by electronic medical record review | Not Posted | 12 months before and after enrollment | Participants | |||||||||||||||||||||||||||||||
| Other Pre-specified | Change in WHO Drinking Risk Level | Change in World Health Organization drinking risk level from baseline. Risk levels are scored 1-4 with higher scores indicating more severe health risk from alcohol use | Posted | Median | Inter-Quartile Range | score on a scale | 3 months after enrollment |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Change in Alcohol Related Life Consequences (Short Inventory of Problems Scale, Version 2R: SIP-2R) | Change in life consequences due to alcohol use from baseline as measured by revised short inventory of problems (score 0-45 with higher scores indicating more severe alcohol related life consequences) | Posted | Median | Inter-Quartile Range | score on a scale | 3 months after enrollment |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Receipt of All Study Naltrexone Injections | Percentage of participants receiving all 3 scheduled naltrexone injections received | Posted | Count of Participants | Participants | 3 months |
|
|
3 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Multimodal Intervention | The intervention is multimodal and consists of:
Extended Release Naltrexone: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant | 0 | 32 | 0 | 32 | 0 | 32 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ralph Wang | University of California, San Francisco | (415) 353-4890 | ralph.wang@ucsf.edu |
| Apr 21, 2023 |
| Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| D019966 | Substance-Related Disorders |
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000624616 | vivitrol |
| D019090 | Case Management |
| ID | Term |
|---|---|
| D010347 | Patient Care Planning |
| D003191 | Comprehensive Health Care |
| D010346 | Patient Care Management |
| D006298 | Health Services Administration |
Not provided
Not provided
| Native American |
|
| LatinX |
|
|
|
|
|
|
|